BertolamiMC. Warning Against Low-Density Lipoprotein Oxidation in Users of Oral
Combined Contraceptives. Arq. Bras.
Cardiol. 2018;111(6):771.
Bertolami,Marcelo Chiara. Warning Against Low-Density Lipoprotein Oxidation in Users of Oral
Combined Contraceptives. Arq. Bras.
Cardiol., v. 111, n. 6, p. 771-771, Dec. 2018.
Bertolami,M.C. (2018). Warning Against Low-Density Lipoprotein Oxidation in Users of Oral
Combined Contraceptives. Arq. Bras.
Cardiol.,111(6), 771-771.
Bertolami,Marcelo Chiara. Warning Against Low-Density Lipoprotein Oxidation in Users of Oral
Combined Contraceptives. Arq. Bras.
Cardiol. [online]. 2018, vol. 111, n. 6, [cited 2025-09-06], pp.771-771. Available from: <https://abccardiol.org/en/short-editorial/warning-against-low-density-lipoprotein-oxidation-in-users-of-oralcombined-contraceptives/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.
